-60%

est. 2Y upside i

HealthcareSeries A

Predicting and preventing heart disease.

Rank

#515

Sector

Health Technology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Bodyport presents a moderate upside opportunity for a job seeker, driven by its FDA-cleared, biomarker-guided digital therapeutic platform and strong clinical results in the rapidly growing remote cardiac monitoring market.

Last updated: March 10, 2026

Bull (28%)+400%

Bodyport achieves widespread adoption of its Cardiac Scale and Fluiditi™ platform, driven by compelling clinical outcomes and new strategic partnerships with major healthcare systems. This leads to significant market penetration in the growing remote cardiac monitoring space, pushing revenue to $75M-$100M by 2028 and justifying a $600M+ valuation at a 6-8x revenue multiple, representing a 4x return from the estimated current valuation.

Base (37%)+75%

Bodyport continues to grow steadily, securing additional contracts with healthcare providers and expanding its patient base for heart failure management. Revenue reaches $30M-$40M by 2028, leading to an estimated valuation of $210M, reflecting a 1.75x return from the estimated current valuation, as the company prepares for a Series B or C round.

Bear (35%)-70%

Bodyport faces increased competition from well-funded incumbents or new market entrants, slower-than-anticipated adoption rates, or challenges in securing its next funding round at a favorable valuation. Revenue growth stalls, leading to a down round or a significantly reduced valuation of $36M, wiping out a substantial portion of common stock value given the existing liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Investors hold $15.8M in liquidation preferences ahead of common stock.

Dilution Risk

high

As a Series A company, Bodyport will likely require further funding rounds (Series B, C, etc.) to scale, which will result in additional dilution for existing common stock holders.

Secondary Liquidity

none

No information suggests active secondary markets or tender offers for Bodyport's equity.

Questions to Ask at the Interview

Strategic questions based on Bodyport's data — designed to show you've done your homework.

  • 1

    “Given the strong clinical results from the SCALE-HF 1 study, what are the key strategies for accelerating adoption among healthcare systems, especially considering the competitive landscape with players like iRhythm and AliveCor?”

  • 2

    “With the remote cardiac monitoring market projected for significant growth, how does Bodyport plan to expand its revenue model beyond contracts with healthcare systems, and what are the next milestones for achieving a Series B or C funding round?”

  • 3

    “Considering the current Series A stage and the preference stack, what is the company's anticipated timeline and strategy for a liquidity event for employees, and how do you foresee the equity value evolving over the next 2-4 years?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.